These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21497188)

  • 21. Current perspectives on stability of protein drug products during formulation, fill and finish operations.
    Rathore N; Rajan RS
    Biotechnol Prog; 2008; 24(3):504-14. PubMed ID: 18484778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical techniques for the evaluation of liquid protein therapeutics.
    Tatford OC; Gomme PT; Bertolini J
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):67-81. PubMed ID: 15270709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viscosity of concentrated therapeutic protein compositions.
    Jezek J; Rides M; Derham B; Moore J; Cerasoli E; Simler R; Perez-Ramirez B
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1107-17. PubMed ID: 22014592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibril Nucleation Kinetics of a Pharmaceutical Peptide: The Role of Conformation Stability, Formulation Factors, and Temperature Effect.
    Zhang J; Mao X; Xu W
    Mol Pharm; 2018 Dec; 15(12):5591-5601. PubMed ID: 30350639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High throughput screening of protein formulation stability: practical considerations.
    Capelle MA; Gurny R; Arvinte T
    Eur J Pharm Biopharm; 2007 Feb; 65(2):131-48. PubMed ID: 17107777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE; Landrum GA; Putta S
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analytical lessons learned from selected therapeutic protein drug comparability studies.
    Federici M; Lubiniecki A; Manikwar P; Volkin DB
    Biologicals; 2013 May; 41(3):131-47. PubMed ID: 23146362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients.
    LaPorte TL; Wang C
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):738-45. PubMed ID: 17987525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel therapeutic strategies for the treatment of protein-misfolding diseases.
    Rochet JC
    Expert Rev Mol Med; 2007 Jun; 9(17):1-34. PubMed ID: 17597554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current approaches in tamper-resistant and abuse-deterrent formulations.
    Mastropietro DJ; Omidian H
    Drug Dev Ind Pharm; 2013 May; 39(5):611-24. PubMed ID: 22537282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pocket extraction on proteins via the Voronoi diagram of spheres.
    Kim D; Cho CH; Cho Y; Ryu J; Bhak J; Kim DS
    J Mol Graph Model; 2008 Apr; 26(7):1104-12. PubMed ID: 18023220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting drug hydrolysis based on moisture uptake in various packaging designs.
    Naversnik K; Bohanec S
    Eur J Pharm Sci; 2008 Dec; 35(5):447-56. PubMed ID: 18940251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein stabilization by cyclodextrins in the liquid and dried state.
    Serno T; Geidobler R; Winter G
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1086-106. PubMed ID: 21907254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of characterizing the crystal form of the drug substance during drug development.
    Clas SD
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):550-60. PubMed ID: 12951818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.